The Role and Mechanism of Innate Immune Regulation in Overcoming Oxaliplatin Resistance and Enhancing Anti-Tumor Efficacy in Colorectal Cancer DOI Creative Commons

Xiaoqing Wang,

Meili Xi, Xing Lü

et al.

Pharmaceuticals, Journal Year: 2025, Volume and Issue: 18(3), P. 317 - 317

Published: Feb. 24, 2025

Background/Objectives: The reversal effect of cGAMP, as a STING pathway regulator, on oxaliplatin resistance in colorectal cancer was investigated, and its mechanism proposed. Methods: efficacy the cGAMP combination for oxaliplatin-resistant through nude mouse tumor model were investigated analyzed, western blot analysis tumors applied. Results: After OXA treatment, IC50 values HCT116 HCT116/L cells 9.04 μmol/L 47.04 μmol/L, respectively. In models, significantly reversed to primary drug-resistant cancer, inhibition rate increased from 8% (oxaliplatin alone) 60% (combination). transplanted model, combined treatment also showed more significant than alone, by 39%, indicating that had considerable improvement acquired resistance. These results fully demonstrated synergistic oxaliplatin. Western enhanced sensitivity down-regulating expression p-PI3K p-AKT up-regulating p53 protein. Conclusions: an immunomodulator against resistance, shows potential application prospect treating cancer.

Language: Английский

The Role and Mechanism of Innate Immune Regulation in Overcoming Oxaliplatin Resistance and Enhancing Anti-Tumor Efficacy in Colorectal Cancer DOI Creative Commons

Xiaoqing Wang,

Meili Xi, Xing Lü

et al.

Pharmaceuticals, Journal Year: 2025, Volume and Issue: 18(3), P. 317 - 317

Published: Feb. 24, 2025

Background/Objectives: The reversal effect of cGAMP, as a STING pathway regulator, on oxaliplatin resistance in colorectal cancer was investigated, and its mechanism proposed. Methods: efficacy the cGAMP combination for oxaliplatin-resistant through nude mouse tumor model were investigated analyzed, western blot analysis tumors applied. Results: After OXA treatment, IC50 values HCT116 HCT116/L cells 9.04 μmol/L 47.04 μmol/L, respectively. In models, significantly reversed to primary drug-resistant cancer, inhibition rate increased from 8% (oxaliplatin alone) 60% (combination). transplanted model, combined treatment also showed more significant than alone, by 39%, indicating that had considerable improvement acquired resistance. These results fully demonstrated synergistic oxaliplatin. Western enhanced sensitivity down-regulating expression p-PI3K p-AKT up-regulating p53 protein. Conclusions: an immunomodulator against resistance, shows potential application prospect treating cancer.

Language: Английский

Citations

0